{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T16:22:24Z","timestamp":1787847744174,"version":"build-2784847793"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Vaso-occlusive crisis (VOC) is one of the main causes of hospital admission in patients with sickle cell disease (SCD). Ketamine is often used as an adjuvant to opioids to control sickle cell crisis; however, there is a lack of evidence about its safety and efficacy for VOC in SCD patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To synthesize evidence from published reports about the efficacy and safety of ketamine in the management of acute painful VOC in both pediatric and adult SCD patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A systematic literature search of PubMed, Scopus, Web of Science, EBSCO and Cochrane Library was conducted, up to March 2019. Studies reporting the analgesic effects and side effects of ketamine in the management of acute painful VOC in pediatric and adult SCD patients were included. The primary outcome measure was improvement in pain scale, and the secondary outcomes were reduction in opioid utilization and side effects. Studies were narratively summarized in this review.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Fourteen studies (with a total of 604 patients) were included in the final analysis. Several case reports and case series showed that ketamine significantly reduced pain scales and opioid utilization in both populations. The only randomized controlled trial available showed that ketamine was noninferior to morphine in reducing pain scores, but had a higher incidence of nonlife-threatening, reversible adverse effects. However, a retrospective study of 33 patients showed a higher pain score in the ketamine group with an acceptable short-term adverse effect.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Ketamine has a potentially comparable efficacy with other opioids in reducing the pain during VOC in SCD patients. However, it also likely has a higher rate of transient adverse events. Owing to the lack of published randomized controlled trials, current evidence is not sufficient to confirm the safety and efficacy of ketamine. Future well-designed randomized controlled trials are strongly recommended.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/sjmms.sjmms_218_20","type":"journal-article","created":{"date-parts":[[2020,12,26]],"date-time":"2020-12-26T01:05:48Z","timestamp":1608944748000},"page":"3-9","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":18,"title":["Ketamine for Sickle Cell Vaso-Occlusive Crises"],"prefix":"10.4103","volume":"9","author":[{"given":"Mohammed S.","family":"Alshahrani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohannad A.","family":"Alghamdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-2-20240909","doi-asserted-by":"crossref","first-page":"e1001484","DOI":"10.1371\/journal.pmed.1001484","article-title":"Global burden of sickle cell anaemia in children under five, 2010-2050: Modelling based on demographics, excess mortality, and interventions. Osrin D, editor","volume":"10","author":"Piel","year":"2013","journal-title":"PLoS Med"},{"key":"R2-2-20240909","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1093\/oxfordjournals.aje.a010288","article-title":"Sickle hemoglobin (HbS) allele and sickle cell disease: A HuGE review","volume":"151","author":"Ashley-Koch","year":"2000","journal-title":"Am J Epidemiol"},{"key":"R3-2-20240909","doi-asserted-by":"crossref","first-page":"g1765","DOI":"10.1136\/bmj.g1765","article-title":"Management of sickle cell disease in the community","volume":"348","author":"Brousse","year":"2014","journal-title":"BMJ"},{"key":"R4-2-20240909","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.1182\/blood-2012-04-383430","article-title":"Sickle cell pain: A critical reappraisal","volume":"120","author":"Ballas","year":"2012","journal-title":"Blood"},{"key":"R5-2-20240909","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/ajh.20336","article-title":"Hospital readmission for adult acute sickle cell painful episodes: Frequency, etiology, and prognostic significance","volume":"79","author":"Ballas","year":"2005","journal-title":"Am J Hematol"},{"key":"R6-2-20240909","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.pain.2009.06.029","article-title":"Pain site frequency and location in sickle cell disease: The PiSCES project","volume":"145","author":"McClish","year":"2009","journal-title":"Pain"},{"key":"R7-2-20240909","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4172\/2155-6148.1000394","article-title":"Low-dose ketamine for children and adolescents with acute sickle cell disease related pain: A single center experience","volume":"05","author":"Neri","year":"2014","journal-title":"J Anesth Clin Res"},{"key":"R9-2-20240909","doi-asserted-by":"crossref","first-page":"145","DOI":"10.36076\/ppj.2011\/14\/145","article-title":"A comprehensive review of opioid-induced hyperalgesia","volume":"14","author":"Lee","year":"2011","journal-title":"Pain Physician"},{"key":"R10-2-20240909","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/AJP.0b013e31816b2f43","article-title":"Opioid-induced Hyperalgesia in Humans","volume":"24","author":"Chu","year":"2008","journal-title":"Clin J Pain"},{"key":"R11-2-20240909","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/j.1476-5381.1983.tb11031.x","article-title":"The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate","volume":"79","author":"Anis","year":"1983","journal-title":"Br J Pharmacol"},{"key":"R12-2-20240909","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/ajh.21676","article-title":"Sickle cell disease in the United States: Looking back and forward at 100 years of progress in management and survival?","volume":"85","author":"Prabhakar","year":"2010","journal-title":"Am J Hematol"},{"key":"R13-2-20240909","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1001\/jama.2012.358","article-title":"Mortality in adults with sickle cell disease and pulmonary hypertension","volume":"307","author":"Mehari","year":"2012","journal-title":"JAMA"},{"key":"R14-2-20240909","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/S0885-3924(98)00144-4","article-title":"Low-dose ketamine in the management of opioid nonresponsive terminal cancer pain","volume":"17","author":"Fine","year":"1999","journal-title":"J Pain Symptom Manage"},{"key":"R15-2-20240909","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/AJP.0b013e3181b511ab","article-title":"Use of low-dose ketamine infusion for pediatric patients with sickle cell disease-related pain","volume":"26","author":"Zempsky","year":"2010","journal-title":"Clin J Pain"},{"key":"R16-2-20240909","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jpainsymman.2013.03.012","article-title":"The role of a low-dose ketamine-midazolam regimen in the management of severe painful crisis in patients with sickle cell disease","volume":"47","author":"Tawfic","year":"2014","journal-title":"J Pain Symptom Manage"},{"key":"R17-2-20240909","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1080\/15360288.2018.1468383","article-title":"Low-dose ketamine infusion for adjunct management during vaso-occlusive episodes in adults with sickle cell disease: A case series","volume":"32","author":"Palm","year":"2018","journal-title":"J Pain Palliat Care Pharmacother"},{"key":"R18-2-20240909","doi-asserted-by":"crossref","first-page":"298","DOI":"10.4103\/0970-9185.168149","article-title":"Role of ketamine for analgesia in adults and children","volume":"32","author":"Vadivelu","year":"2016","journal-title":"J Anaesthesiol Clin Pharmacol"},{"key":"R19-2-20240909","first-page":"13","article-title":"A triple-option analgesia plan for tactical combat casualty care: TCCC Guidelines Change 13-04","volume":"14","author":"Butler","year":"2014","journal-title":"J Spec Oper Med"},{"key":"R20-2-20240909","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.accpm.2015.04.005","article-title":"Ketamine for pain management in France, an observational survey","volume":"34","author":"Martinez","year":"2015","journal-title":"Anaesth Crit Care Pain Med"},{"key":"R21-2-20240909","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"R22-2-20240909","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"R23-2-20240909","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"key":"R24-2-20240909","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","article-title":"Methodological Index for Non-Randomized Studies (MINORS): Development and validation of a new instrument","volume":"73","author":"Slim","year":"2003","journal-title":"ANZ J Surg"},{"key":"R25-2-20240909","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1515\/sjpain-2017-0140","article-title":"Low dose ketamine versus morphine for acute severe vaso occlusive pain in children: A randomized controlled trial","volume":"18","author":"Lubega","year":"2018","journal-title":"Scand J Pain"},{"key":"R26-2-20240909","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/pr.2017.197","article-title":"Patient characteristics affect the response to ketamine and opioids during the treatment of vaso-occlusive episode-related pain in sickle cell disease","volume":"83","author":"Nobrega","year":"2018","journal-title":"Pediatr Res"},{"key":"R27-2-20240909","doi-asserted-by":"crossref","first-page":"787","DOI":"10.2147\/JPR.S131156","article-title":"Subanesthetic ketamine for pain management in hospitalized children, adolescents, and young adults: A single-center cohort study","volume":"10","author":"Sheehy","year":"2017","journal-title":"J Pain Res"},{"key":"R28-2-20240909","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1182\/blood.V122.21.2249.2249","article-title":"Molokie; Low-Dose Ketamine Infusion In Adult Patients With Sickle Cell Disease \u2013 Impact On Management Of Acute Painful Episodes","volume":"122","author":"Michel","year":"2013","journal-title":"Blood"},{"key":"R29-2-20240909","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1016\/j.jpain.2017.02.348","article-title":"(374) Ketamine infusion as an analgesic adjunct in the management of severe pain in patients with sickle cell disease","volume":"18","author":"Hassell","year":"2017","journal-title":"J Pain"},{"key":"R30-2-20240909","first-page":"20","article-title":"Evaluating the use of ketamine for pain control with sickle cell crisis in pregnancy","volume":"10","author":"Gimovsky","year":"2018","journal-title":"A Case Rep"},{"key":"R31-2-20240909","doi-asserted-by":"crossref","first-page":"150","DOI":"10.3109\/15360288.2013.788599","article-title":"Oral ketamine for sickle cell crisis pain refractory to opioids","volume":"27","author":"Jennings","year":"2013","journal-title":"J Pain Palliat Care Pharmacother"},{"key":"R32-2-20240909","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s00277-013-1954-3","article-title":"Ketamine infusion for sickle cell pain crisis refractory to opioids: D case report and review of literature","volume":"93","author":"Uprety","year":"2014","journal-title":"Ann Hematol"},{"key":"R33-2-20240909","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1016\/j.jpainsymman.2011.06.003","article-title":"Ketamine infusion for sickle cell crisis pain in an adult","volume":"42","author":"Meals","year":"2011","journal-title":"J Pain Symptom Manage"},{"key":"R34-2-20240909","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1089\/jpm.2010.0424","article-title":"The use of ketamine in severe cases of refractory pain syndromes in the palliative care setting: A case series","volume":"14","author":"Kerr","year":"2011","journal-title":"J Palliat Med"},{"key":"R35-2-20240909","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.pain.2004.01.035","article-title":"Modulation of morphine analgesia by site-specific N-methyl-d-aspartate receptor antagonists: Dependence on sex, site of antagonism, morphine dose, and time","volume":"109","author":"Nemmani","year":"2004","journal-title":"Pain"},{"key":"R36-2-20240909","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.neuroscience.2015.01.008","article-title":"Sex differences in the rapid and the sustained antidepressant-like effects of ketamine in stress-na\u00efve and \u201cdepressed\u201d mice exposed to chronic mild stress","volume":"290","author":"Franceschelli","year":"2015","journal-title":"Neuroscience"},{"key":"R37-2-20240909","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/hup.2475","article-title":"The use of ketamine as an antidepressant: A systematic review and meta-analysis","volume":"30","author":"Coyle","year":"2015","journal-title":"Hum Psychopharmacol Clin Exp"},{"key":"R38-2-20240909","doi-asserted-by":"crossref","first-page":"e017190","DOI":"10.1136\/bmjopen-2017-017190","article-title":"Subdissociative intranasal ketamine plus standard pain therapy versus standard pain therapy in the treatment of paediatric sickle cell disease vaso-occlusive crises in resource-limited settings: Study protocol for a randomised controlled trial","volume":"7","author":"Young","year":"2017","journal-title":"BMJ Open"}],"container-title":["Saudi Journal of Medicine &amp; Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/sjmms.sjmms_218_20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T15:35:29Z","timestamp":1787844929000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/sjmms.sjmms_218_20"}},"subtitle":["A Systematic Review"],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.4103\/sjmms.sjmms_218_20","relation":{},"ISSN":["1658-631X"],"issn-type":[{"value":"1658-631X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]}}}